Open House Biologika Rabattverträge 2025-13 - Insulin-Isophan/insulin, Normal (human) (wirkstoffkombination)

Health, Health, Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

July 30, 2027
Response Due
Active
Status

Opportunity Overview

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2025-13 - Insulin-isophan/Insulin, normal (human) (Wirkstoffkombination)

This is one of 1,752 active Germany Health Services opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHealth, Health, Health
CountryGermany
CategoryHealth Services
PublishedMay 12, 2025
Procurement stageActive solicitation
Response dueJuly 30, 2027
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 10, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Related Opportunities in Germany

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tamsulosin und Dutasterid, ATC G04CA52
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Peginterferon beta-1a, ATC L03AB13
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-07 - Lamivudin/Abacavir/Dolutegravir (Wirkstoffkombination)
Germany – Pharmaceutical products – Arzneimittel mit der Wirkstoffkombination Brinzolamid und Timolol (ATC: S01ED67)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Bempedoinsäure, (OBO) ATC C10AX15 für die Zeit 01.03.2025 - 28.02.2027
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Tolvaptan (ATC-Code: C03XA01)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Isosorbidmononitrat, ATC C01DA14 für die Zeit 01.03.2026 - 29.02.2028 (zzgl. Verlängerungsoption 1x12 Monate)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V mit der Wirkstoffkombination Adapalen + Benzoylperoxid

See every Germany Health Services opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Health Services intelligence report in your inbox

A personalized report on Germany Health Services opportunities, emailed in 5-10 minutes. One per month, no account needed.